baber/WOPTO huggingface dataset:
Patent NZ-566105-A (NZ)
Title: Road traffic-control signboard assembly having automatic return function
Inventor: KIM KI RYONG
IPC: E01F9/669
Filed: 2006-07-21
Abstract: A road sign assembly where the signboard can return to its correct orientation after impact is disclosed. The assembly includes an elastic body (30) that wraps around a stay bar (1) of a road sign, and a clamp (10, 20) that encircles the elastic body. The clamp is connected to a support plate (70) by a hinge. The support plate and a reinforcement plate (60) are connected to the signboard. A tension spring (80) extends from an upper region of the reinforcement plate to the upper section (10) of the clamp. The spring acts to return the signboard to a vertical orientation if the signboard is moved by an external force.
Patent NZ-569181-A (NZ)
Title: Pressurised medical device with supplementary pressure sensor
Inventor: ROWLEY DUNCAN JOHN
IPC: A61H23/04
Filed: 2007-01-24
Abstract: Disclosed is a pressurised medical device. The device comprises of: an inflatable element arranged to contact a part of a patient; a fluid connector attached to the element and arranged to deliver fluid to the element; a control system arranged to control flow of fluid in the device; a first element pressure sensor arranged to measure the pressure exerted by the element on the part of the patient; and detection means arranged to detect malfunctioning of the first element pressure sensor. The detection means comprises a reference pressure sensor arranged to independently measure the pressure exerted by the element on the part of the patient.
Patent NZ-571995-A (NZ)
Title: Diketo-piperazine and piperidine derivatives as antiviral agents
Inventor: WANG TAO
IPC: C07D403/12
Filed: 2007-04-16
Abstract: Disclosed is a compound selected from the group consisting of by way of example 2-(4-Fluoro-7-(1H-1,2,3-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoacetic acid for treating a mammal infected with HIV.
Patent NZ-574285-A (NZ)
Title: Treatment of pulmonary disease conditions
Inventor: CRUMP DAVID ERIC
IPC: A61K38/18
Filed: 2007-08-10
Abstract: Disclosed is the use of a granulocyte-colony stimulating factor (G-CSF) signalling inhibitor selected from the group consisting of: a. an antibody specific for G-CSF; and b. an antibody specific for G-CSFR; in the manufacture of a medicament for the treatment of a pulmonary disease associated with neutrophil infiltration in a subject.
Patent NZ-575768-A (NZ)
Title: Process for the preparation of catalysts using a pulse-flow reactor
Inventor: CAMPBELL GRAEME DOUGLAS
IPC: B01F11/00
Filed: 2007-10-18
Abstract: A process for manufacturing a catalyst composition comprising the steps of: (i) precipitating one or more metal compounds from solution using an alkaline precipitant, optionally in the presence of a thermostabilising material, (ii) ageing the precipitated composition, and (iii) recovering and drying the aged composition, wherein the ageing step is performed using a pulse-flow reactor. The precipitated metal compounds may comprise compounds of one or more metals selected from Ca, Mg, Ti, V, Cr, Mn, Fe, Cr, Co, Ni, Cu, Zn, or Pb. The thermostabilising material includes a metal oxide powder, gel or sol, preferably alumina sol. The alkaline precipitant comprises an alkali metal carbonate such as sodium carbonate or potassium carbonate.
Patent NZ-580396-A (NZ)
Title: Naphthalene isoxazoline invertebrate pest control agents
Inventor: LAHM GEORGE PHILIP
IPC: A01N43/80
Filed: 2008-06-20
Abstract: Disclosed is a compound of formula (I), wherein the substituents are as defined in the specification, and processes for their preparation.  The compounds are isoxazolines useful in invertebrate pest control.
Patent NZ-582828-A (NZ)
Title: Alpha7 nachr agonists for treating or preventing metabolic disorders
Inventor: MARRERO MARIO B
IPC: A61P43/00
Filed: 2008-08-01
Abstract: Disclosed is the use of a selective a7 nAChR agonist bicyclo bridged comprising herterocycles and carboxamide compound of Formula 1 or a pharmaceutically acceptable salt thereof. in the manufacture of a medicament for treating or preventing metabolic syndrome. A compound of formula (I) is (2S,3R)-N-(2-((3-Pyridinyl)methyl)-1-azabicyclo[2.2.2]octan-3-yl)benzofuran-2-carboxamide.
Patent NZ-585103-A (NZ)
Title: Substituted lactams derivatives and their uses for glaucoma and ocullar hypertension
Inventor: OLD DAVID W
IPC: A61P27/06
Filed: 2008-10-16
Abstract: Disclosed are lactam derivatives and their uses in treatment of glaucoma and hypertension.
Patent NZ-586418-A (NZ)
Title: Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
Inventor: SPRINGER CAROLINE JOY
IPC: A61K31/4375
Filed: 2008-12-19
Abstract: Disclosed are 8-aryloxy-pyrido[2,3-b]pyrazine, 8-aryloxy-pyrido[3,2-b]pyrazin-3-one and 8-aryloxy-2-oxo-1,2-dihydropyrido[2,3-b]pyrazine derivatives as represented by the general formula, wherein RQ1 is independently H, R1, R1X, Cl, OH, OR1, OR1x, SH, SR1, NH2, NHR1, NR12 or NRRARRB; RQ2 is independently H, R2, R2X, Cl, OH, OR2, OR2x, SH, -SR2, NH2, NHR2, NR22 or NRRCRRD; X is independently O, S, S(=O), or SO2; M is an optionally substituted phenyl or naphthalene group as defined herein; L is a nitrogen containing linker (as defined herein); and J is an optionally substituted phenyl or C5-6heteroaryl moiety; and wherein the remaining substituents are as defined herein. Representative compounds include 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-(2-oxo-1,2-dihydro-pyrido[2,3-b]pyrazin-8-yloxy)phenyl)urea, 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(4-(3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yloxy)phenyl)urea, 1-(2-fluoro-4-(3-methyl-2-oxo-1,2-dihydropyrido[3,2-b]pyrazin-8-yloxy)phenyl)-3-(2-fluoro-5-(trifluoromethyl} phenyl)urea, N-(3-(3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yloxy)phenyl)-3-(trifluoromethoxy)benzamide and 3-tert-butyl-N-(3-(3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yloxy)phenyl)benzamide. Further disclosed is a pharmaceutical composition which comprises a compound as defined above, and a pharmaceutically acceptable carrier or diluent, for the treatment of a disease or disorder that is ameliorated by the inhibition of RAF function, and particularly for the treatment of proliferative disorders including cancer, melanoma and for the treatment of colorectal cancer.
Patent NZ-589805-A (NZ)
Title: Foodstuffs container comprising a structural layer coated with an acrylic polymer
Inventor: PROPST CHARLES
IPC: B32B27/08
Filed: 2009-06-01
Abstract: Disclosed is a foodstuff container comprising a structural layer coated with a coating layer, wherein the structural layer comprises a component selected from the group consisting of paper, paperboard, corrugated paper, bag stock, ream wrap, roll wrap, folding board, solid fibre, and combinations thereof, wherein the coating layer is a polymer formed from a monomer selected from the group consisting of methyl methacrylate, isobutyl acrylate, 2-ethyl acrylate, butyl methacrylate, isobutyl methacrylate, 2-ethyl methacrylate, and mixtures thereof, and wherein the coating layer prevents a foodstuff from sticking to the structural layer, and further comprising a foodstuff in contact with the coating layer.
Patent NZ-603638-A (NZ)
Title: An apparatus and method of stunning an animal which is reversible comprising a microwave generator and waveguide
Inventor: RALPH JAMES HENRY
IPC: A22B3/00
Filed: 2011-05-09
Abstract: 603638 Disclosed is an animal stunning apparatus and a method of stunning an animal. The animal stunning apparatus allows a reversible process, so slaughtered animals will be eaten by different ethnicities. The apparatus induces substantially immediate unconsciousness and insensibility. The apparatus comprises a stunning station (10); an applicator (60); a microwave generator (75) and a switching means (78). The live animal to be processed is brought to the stunning station (10) and is arranged in a confined position. The applicator (60) is located so it can contact an application point on a frontal portion of the live animal's brain. The applicator (60) has a coupling conformation to couple microwave radiation to the head and to the frontal portion of the brain when the animal is in the confined position. The microwave generator (75) generates and radiates microwave energy of suitable power level and frequency. A waveguide (76) is coupled to the generator (75) to receive and direct the microwave radiation to the applicator (60) located at an operative end (77) of the waveguide (76) to heat the frontal portion of the brain of the animal beneath the application point. The switching means (78) is operable to discontinue the application of the microwave radiation effecting heating of the frontal portion of the brain after a period of time. After the period of time, unconsciousness and insensibility is induced.
Patent NZ-607450-A (NZ)
Title: Self-serve kiosk with rotatable container carousel
Inventor: ADAMS JOSEPH L
IPC: G07F11/54
Filed: 2012-03-23
Abstract: A self-serve kiosk is disclosed for storing and dispensing tanks such as LPG tanks. The kiosk comprises a main frame and a carousel (53) rotatably mounted about a vertical axis of rotation. The carousel has a plurality of separate shelves (54, 55, 56) located around the axis on a plurality of levels and a plurality of doors are hingedly mounted to the main frame. A driver is mounted on the main frame and engaged with the carousel (53) for rotating the carousel. The driver includes a driver such as a gas cylinder and piston which drives a spring loaded piston projecting from the bottom wall (44) of the frame to engage the carousel (53). A lock is mounted on the frame for selectively limiting movement of the carousel (53).
Patent NZ-608435-A (NZ)
Title: Automatic solar tracking adjustment/control apparatus of solar generation system
IPC: F24S50/20
Filed: 2013-03-19
Abstract: Disclosed is an automatic solar tracking adjustment/control apparatus of a solar generation system. The apparatus is comprised of a support assembly, a carrier platform, at least one drive assembly and a detection/correction module. The support assembly includes a support seat disposed at one end of the support assembly. The carrier platform is disposed on the support seat via a two-dimensionally-movable pivotal rotational assembly. At least one solar generation module is disposed on the carrier platform for converting solar energy into electrical energy. The at least one drive assembly is disposed between the support assembly and the carrier platform and serves to drive the carrier platform according to reference parameters previously stored in a control unit. The carrier platform can be tilted in different directions and different inclination angles around the pivotal rotational assembly. The detection/correction module is disposed on the carrier platform for detecting and obtaining actual parameters including tilting direction and inclination angle of the carrier platform and feeding the actual parameters back to the control unit. The control unit compares the actual parameters with the previously stored reference parameters to obtain a comparison result. According to the comparison result, the control unit modifies the tilting direction and inclination angle of the carrier platform via the drive assembly. The drive assembly includes flexible connection members, such as cables, connected to opposite corners of the carrier platform.
Patent NZ-612093-A (NZ)
Title: Modulators of pharmacokinetic properties of therapeutics
Inventor: LIU HONGTAO
IPC: C07D417/14
Filed: 2008-02-22
Abstract: Disclosed is a pharmaceutical composition comprising cobicistat / GS-9350 (as represented by formula IIBa) or a pharmaceutically acceptable salt thereof, in combination with two or three additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, emtricitabine, elvitegravir, efavirenz, atazanavir, darunavir, raltegravir, rilpivirine, and tenofovir alafenamide fumarate (GS-7340); wherein the compound of formula IIBa or pharmaceutically acceptable salt thereof is not in combination with tenofovir disoproxil fumarate, emtricitabine and elvitegravir, for treating an HIV infection or HCV infection in a human patient. Also disclosed is the use of cobicistat / GS-9350 (as represented by formula IIBa) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for improving the pharmacokinetics of two or three additional therapeutic agents which are metabolized by cytochrome P450 monooxygenase or increasing the blood plasma level of the added therapeutic agents which are metabolized by cytochrome P450 monooxygenase, wherein the medicament is formulated for simultaneous, sequential or separate administration with a combination of said two or three additional therapeutic agents selected from the group consisting of tenofovir disoproxil fumarate, emtricitabine, elvitegravir, efavirenz, atazanavir, darunavir, raltegravir, rilpivirine, and GS-7340; wherein the combination of two or three additional therapeutic agents is not tenofovir disoproxil fumarate, emtricitabine and elvitegravir.
Patent NZ-617245-A (NZ)
Title: Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
Inventor: WALLIN JEFFREY
IPC: C07D239/70
Filed: 2012-03-30
Abstract: Disclosed herein is a combination comprising a) compound of formula Ia 2-(4-chlorophenyl)-3-(isopropylamino)-1-(4-((R)-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)propan-1-one (GDC-0068/ipatasertib) or a pharmaceutically acceptable salt thereof and 5-FU (fluorouracil) and/or capecitabine. Also disclosed is the use of the combinations for treating hyperproliferative disorders, such as cancer.
Patent NZ-623294-A (NZ)
Title: Stabilized alpha-galactosidase and uses thereof
Inventor: AZULAY YANIV
IPC: C12N9/40
Filed: 2011-03-02
Abstract: Disclosed is a pharmaceutical composition comprising: a water-soluble multimeric protein structure comprising at least two α-galactosidase monomers being covalently linked to one another via a linking moiety, wherein said linking moiety is not present in native α-galactosidase; and a pharmaceutically acceptable carrier.
Patent NZ-623642-A (NZ)
Title: Lasp-1, a novel urinary marker for transitional cell carcinoma detection
Inventor: BUTT ELKE
IPC: G01N33/574
Filed: 2012-12-06
Abstract: Disclosed is the use of LASP-1 in a urine sample obtained from a subject for diagnosing and/or grading transitional cell carcinoma, wherein the presence of LASP-1 above 1 ng/500 µl urine is indicative for transitional cell carcinoma, and an increase of LASP-1 expression correlates with a higher grading of the transitional cell carcinoma. Also disclosed is a method for diagnosing transitional cell carcinoma comprising detecting the presence or absence of LASP-1 in a urine sample obtained from a subject, wherein the presence of LASP-1 above 1 ng/500 µl urine is indicative for transitional cell carcinoma. Also disclosed is a method for grading transitional cell carcinoma comprising determining the level of LASP-1 in a urine sample obtained from a subject, wherein the level of LASP-1 correlates with the grade of the transitional cell carcinoma.
Patent NZ-623936-A (NZ)
Title: Gas injection moulding bike
Inventor: RICHARD DAVID BARNABY LATHAM
IPC: B62K19/16
Filed: 2013-05-29
Abstract: 623936 A bike (1) is disclosed. The bike comprises at least two wheels (2, 3) for conveying the bike over a ground surface, a frame member (6, 7) supported between at least one front wheel and at least one rear wheel, the wheels being located approximate each distal end of the frame, a handle bar (5) at the front wheel end of the bike in communication with the front wheel(s) and first distal end of the frame, and a seat (9) on which the rider may sit when the bike is used. At least one part selected from: part or all of the frame member, the handle bar, or the seat, are hollow tubular plastic sections manufactured via gas injection moulding. This is advantageous in that the particular part formed via gas injection moulding has a lower weight, an aesthetically pleasing finish, and strength and uniformity in wall width.
Patent NZ-702574-A (NZ)
Title: Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
Inventor: TOMINAGA YUICHI
IPC: C07D487/04
Filed: 2013-06-03
Abstract: The present invention provides a compound useful in treating tumors by ROS1 kinase enzyme activity inhibitory action and NTRK kinase enzyme inhibitory action, or a pharmacologically acceptable salt thereof. A compound having an imidazo[1,2-b]pyridazine structure represented by general formula (I), a pharmacologically acceptable salt thereof, or pharmaceutical compositions comprising such compounds. (In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined in the present description.)
Patent NZ-716598-A (NZ)
Title: Anthelmintic compounds and compositions and method of using thereof
Inventor: MENG CHARLES Q
IPC: C07D417/12
Filed: 2013-11-19
Abstract: The present invention relates to anthelmintic compounds of the formula below: wherein Y is benzothiazolyl or benzoxazolyl, optionally substituted by one or more of halogen, haloalkyl, alkoxy, haloalkoxy, alkylthio, halothio or haloalkylthio; and Z is phenyl substituted with one or more halogen, nitro, cyano, haloalkyl or haloalkoxy, provided that said phenyl comprises a para-nitro or para-cyano group; and variables X8 and W are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
Patent NZ-726608-A (NZ)
Title: Phosphatidylinositol 3-kinase inhibitors
Inventor: PHILLIPS BARTON
IPC: C07D513/04
Filed: 2015-06-10
Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A’, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3 -kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.
Patent NZ-728372-A (NZ)
Title: Human-derived anti-huntingtin (htt) antibodies and uses thereof
Inventor: GRIMM JAN
IPC: C07K14/47
Filed: 2015-07-29
Abstract: Provided are novel human-derived anti-huntingtin (HTT) antibodies and biotechnological derivatives thereof, preferably capable of binding mutated and/or aggregated HTT species and or fragments thereof, as well as methods related thereto. The human-derived anti-HTT antibodies and biotechnological derivatives can be used in pharmaceutical and diagnostic compositions for HTT targeted immunotherapy of Huntington Disease and diagnosis thereof.
Patent NZ-737850-A (NZ)
Title: Extended-range spray applicator
Inventor: LESLIE CHRISTOPHER
IPC: B05B3/10
Filed: 2016-05-13
Abstract: The disclosure relates to a spray applicator comprising an air supply, a shroud mounted on and in fluid communication with the air supply, and a liquid atomizer rotatably mounted on the air supply and a secondary shroud detachably positioned between the shroud and the liquid atomizer. The disclosure also relates to using the spray applicator for dosing vaccines and/or probiotics to avian animals at a distance.
Patent NZ-738682-A (NZ)
Title: Extended release pharmaceutical compositions of levetiracetam
Inventor: GALLAGHER MICHELA
IPC: A61K9/20
Filed: 2016-05-20
Abstract: This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof.
Patent NZ-750551-A (NZ)
Title: Multi-layer diffractive eyepiece
Inventor: SCHOWENGERDT BRIAN T
IPC: G02B27/01
Filed: 2017-08-22
Abstract: An eyepiece for projecting an image to an eye of a viewer includes a waveguide configured to propagate light in a first wavelength range, and a grating coupled to a back surface of the waveguide. The grating is configured to diffract a first portion of the light propagating in the waveguide out of a plane of the waveguide toward a first direction, and to diffract a second portion of the light propagating in the waveguide out of the plane of the waveguide toward a second direction opposite to the first direction. The eyepiece furthers include a wavelength-selective reflector coupled to a front surface of the waveguide. The wavelength selective reflector is configured to reflect light in the first wavelength range and transmit light outside the first wavelength range, such that the wavelength-selective reflector reflects at least part of the second portion of the light back toward the first direction.
Patent NZ-753721-A (NZ)
Title: Filter system
Inventor: HALES ERIC
IPC: E04H4/14
Filed: 2016-12-22
Abstract: A system for filtering water in a spa that provides safety and greater filtration as well as increased ease of mineral cartridge replacement. The system may include a filter secured to a core. The core may include first and second cages with a plurality of openings allowing water to freely pass through the filter and core while preventing larger objects from passing through. The first cage may provide an orientation feature to position the filter in one direction. The second cage may hold mineral cartridges. The core may be secured to a fitting that is secured to the suction line of a spa via a ratchet like engagement feature. The fitting and core prevent back out of the core unless manually overriding the arm on the core which engages fins on the fitting. The filter may be removed and replaced while the core remains in place providing safety to the user. A cap secures the whole assembly into place.
Patent NZ-756392-A (NZ)
Title: Pd-l1 variant immunomodulatory proteins and uses thereof
Inventor: SWANSON RYAN
IPC: C07K14/705
Filed: 2018-03-13
Abstract: Provided herein are immunomodulatory proteins comprising variant PD-Ll and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
Patent NZ-757330-A (NZ)
Title: Intermediated access to entity information profiles
Inventor: JUGOVIC ERNEST
IPC: G06Q10/10
Filed: 2017-04-12
Abstract: A profile database contains a plurality of profile records, each made up of at least one subject information element of a subject entity. Subscribers, via subscribed devices, can subscribe to and submit updates to subject information elements of entities contained in the database. The database holds the details of authorized subscriptions to particular subject information elements, and the contents of subscribed information elements are made available to subscriber devices of the authorized subscribers as required. All subscription requests and updates to the profile records are approved on behalf of the related entity.
Patent NZ-761097-A (NZ)
Title: Data carrier with tactile printed area for ink writing data
Inventor: KASKIALA TONI
IPC: B42D25/425
Filed: 2018-06-29
Abstract: The present invention relates generally to a data carrier comprising a data sheet. Said data sheet comprises a substrate material wherein at least one printed area is printed. Said printed area is configured for ink written signature. Said printed area is produced by imprinting via intaglio printing and comprises tactile perceptibility structured embossed pattern produced by the imprinting. Said tactile structured embossed pattern is configured to hold the ink of the ink written. The present invention prevents unwanted smudging or spreading when writing on the printed area. Moreover, the present invention addresses also the forgery and manipulation drawbacks on ink written data on data carrier.